SCHEMBL3587044

SCHEMBL3587044

N#Cc1ccc(CCN2CCC(NC(=O)O)CC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.60
KCNJ1 P48048 2/20 0.60
SIGMAR1 Q99720 1/20 0.57
DRD4 P21917 3/20 0.55
HTR2A P28223 2/20 0.55
CACNA1F O60840 1/20 0.55
HTR1A P08908 1/20 0.55
ADORA3 P0DMS8 1/20 0.55
DRD2 P14416 1/20 0.55
CNR1 P21554 1/20 0.55
DRD1 P21728 1/20 0.55
DRD5 P21918 1/20 0.55
SLC6A2 P23975 1/20 0.55
HRH2 P25021 1/20 0.55
ADRA1D P25100 1/20 0.55
HTR1B P28222 1/20 0.55
HTR2C P28335 1/20 0.55
HTR7 P34969 1/20 0.55
ADRA1A P35348 1/20 0.55
HRH1 P35367 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4305546 0.84 L3MBTL1 (0.64) KCNH2SIGMAR1DRD4HRH1OPRM1
SCHEMBL27430491 0.84 SIGMAR1 (0.79) SIGMAR1DRD4HTR2ACXCR3
SCHEMBL22233246 0.83 SIGMAR1 (0.61) SIGMAR1DRD4HTR2ACXCR3L3MBTL1
SCHEMBL3587801 0.83 SIGMAR1 (0.61) KCNH2SIGMAR1DRD4DRD2OPRM1
SCHEMBL3674402 0.82 SIGMAR1 (0.61) KCNH2KCNJ1SIGMAR1DRD4HTR2A
SCHEMBL3935469 0.82 SIGMAR1 (0.67) SIGMAR1DRD4HTR2ADRD2CXCR3
SCHEMBL3637147 0.79 L3MBTL1 (0.57) SIGMAR1PRKAA2L3MBTL1
SCHEMBL8409284 0.78 KCNH2 (0.55) KCNH2KCNJ1HTR2AHRH2HTR2C
SCHEMBL3643385 0.78 L3MBTL1 (0.56) SIGMAR1PRKAA2L3MBTL1
SCHEMBL7723132 0.77 KCNH2 (0.47) KCNH2KCNJ1SIGMAR1DRD4HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP claimed
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2010-11-04 US disclosed
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP disclosed
EP-1720550-A1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS Sanofi-Aventis (FR) 2006-11-15 EP disclosed
WO-2005089759-A1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 KCNH2 920/4885KCNJ1 1933/4885SIGMAR1 2487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.